Literature DB >> 4359938

Direct inhibitory effect of hypercalcemia on renal actions of parathyroid hormone.

N Beck, H Singh, S W Reed, B B Davis.   

Abstract

The effects of calcium on the renal actions of parathyroid hormone (PTH) were studied in vivo and in vitro. In parathyroidectomized rats, variable levels of blood calcium concentration were induced by intravenous infusion of calcium. The renal responses to the injected PTH, i.e. phosphate and cyclic AMP excretion, were compared in these animals. After PTH injection, the increases of both phosphate and cyclic AMP excretion were less in the calcium-infused animals than in the control group without calcium infusion. There was an inverse correlation between the renal responses to PTH and plasma calcium concentration of 4.2-13.5 mg/100 ml. But calcium had no effect on phosphate excretion induced by infusion of dibutyryl cyclic AMP. In the in vitro experiments, the increase of cyclic AMP concentration in response to PTH was less in renal cortical slices taken from the calcium-infused animals than in ones from the control group without calcium infusion. Calcium also inhibited the activation of renal cortical adenylate cyclase in response to PTH, but calcium had no effect on phosphodiesterase. The data indicate that calcium directly inhibits renal actions of PTH both in vivo and in vitro. Such inhibitory mechanism is probably at or before the step of PTH-dependent cyclic AMP generation in the kidney.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4359938      PMCID: PMC333052          DOI: 10.1172/JCI107610

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  THE EXCRETION OF INULIN, XYLOSE AND UREA BY NORMAL AND PHLORIZINIZED MAN.

Authors:  J A Shannon; H W Smith
Journal:  J Clin Invest       Date:  1935-07       Impact factor: 14.808

2.  Mode of action of parathyroid hormone and cyclic adenosine 3',5'-monophosphate on renal tubular phosphate reabsorption in the dog.

Authors:  Z S Agus; J B Puschett; D Senesky; M Goldberg
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

3.  A method for determination of 3',5'-cyclic adenosine monophosphate based on adenosine triphosphate formation.

Authors:  T Kaneko; J B Field
Journal:  J Lab Clin Med       Date:  1969-10

4.  Properties of cyclic 3',5'-nucleotide phosphodiesterase from rat brain.

Authors:  W Y Cheung
Journal:  Biochemistry       Date:  1967-04       Impact factor: 3.162

5.  Parathyroid function and the renal excretion of 3'5'-adenylic acid.

Authors:  L R Chase; G D Aurbach
Journal:  Proc Natl Acad Sci U S A       Date:  1967-08       Impact factor: 11.205

6.  Regulation of parathyroid hormone secretion: proportional control by calcium, lack of effect of phosphate.

Authors:  L M Sherwood; G P Mayer; C F Ramberg; D S Kronfeld; G D Aurbach; J T Potts
Journal:  Endocrinology       Date:  1968-11       Impact factor: 4.736

7.  Measurement of single-nephron glomerular filtration rate by micropuncture: analysis of error.

Authors:  V E Andreucci; J Herrera-Acosta; F C Rector; D W Seldin
Journal:  Am J Physiol       Date:  1971-12

8.  Renal cortical adenyl cyclase: effect of parathyroid hormone and calcium.

Authors:  J M Streeto
Journal:  Metabolism       Date:  1969-11       Impact factor: 8.694

9.  Renal adenyl cyclase: anatomically separate sites for parathyroid hormone and vasopressin.

Authors:  L R Chase; G D Aurbach
Journal:  Science       Date:  1968-02-02       Impact factor: 47.728

10.  Adenyl cyclase and hormone action. 3. Calcium requirement for ACTH stimulation of adenyl cyclase.

Authors:  H P Bär; O Hechter
Journal:  Biochem Biophys Res Commun       Date:  1969-06-06       Impact factor: 3.575

View more
  12 in total

1.  Dissociation of renal cyclic AMP and phosphate responses to parathyroid hormone in uremia.

Authors:  J E Russell; M Kleerekoper; E Slatopolsky; J Lewis; S W Lee; L V Avioli
Journal:  Calcif Tissue Int       Date:  1979-11-26       Impact factor: 4.333

2.  Inhibition of carbonic anhydrase by parathyroid hormone and cyclic AMP in rat renal cortex in vitro.

Authors:  N Beck; K S Kim; M Wolak; B B Davis
Journal:  J Clin Invest       Date:  1975-01       Impact factor: 14.808

Review 3.  Familial hypocalciuric hypercalcaemia--familial benign hypercalcaemia: a review.

Authors:  J Auwerx; J Brunzell; R Bouillon; M Demedts
Journal:  Postgrad Med J       Date:  1987-10       Impact factor: 2.401

4.  Phosphate transport in the proximal convolution of the rat kidney II. Effect of extracellular Ca2+ and application of the Ca2+ ionophore A 23187 in chronic PTX animals.

Authors:  K J Ullrich; G Rumrich; S Klöss
Journal:  Pflugers Arch       Date:  1978-06-21       Impact factor: 3.657

5.  Evidence for a parathyroid hormone-independent calcium modulation of phosphate transport along the nephron.

Authors:  C Amiel; H Kuntziger; S Couette; C Coureau; N Bergounioux
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

6.  Mechanism of resistance to the phosphaturic effect of the parathyroid hormone in the hamster.

Authors:  F G Knox; J Preiss; J K Kim; T P Dousa
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

7.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.

Authors:  A E Broadus; J E Mahaffey; F C Bartter; R M Neer
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

8.  Inhibition of renal adenylate cyclase by plasma from uremic patients.

Authors:  H Jüppner; R D Hesch
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

9.  Pathogenic role of cyclic AMP in the impairment of urinary concentrating ability in acute hypercalcemia.

Authors:  N Beck; H Singh; S W Reed; H V Murdaugh; B B Davis
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

10.  Renal refractoriness to PTH in experimental Fanconi syndrome: evidence for intact adenylate cyclase activation.

Authors:  H Wald; M M Popovtzer
Journal:  Pflugers Arch       Date:  1984-09       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.